Patent application number | Description | Published |
20090009512 | IMAGING SYSTEM - The present invention relates to an imaging system for displaying a structure of temporally changing configuration. The imaging system comprises a display rendering means which processes the image data representative of the structure, renders a display representative of the structure and a presents a display panel of key data indicia which relates to the key data of the structure. The data indicia is targeted within a two stage process, which first causes the relevant computer generated trace image related to the data indicium to be superposed upon the relevant ultrasound image. The second stage provides the option of selecting the data indicium to further reveal information about the structure. Such an interaction provides all the data related to a key measurement and not just the end result, without cluttering the display images by displaying all the image data simultaneously. | 01-08-2009 |
20090027379 | IMAGING SYSTEM - The present invention relates to an imaging system for displaying image data representative of a structure investigated by scan image data acquisition means. The imaging system comprises display rendering means for processing scan data representative of the configuration of the structure and rendering a display comprising a 3D image of the structure superposed with a scan image representative of the extent of the scan region. | 01-29-2009 |
20090141953 | IMAGING SYSTEM - The present invention relates to an imaging system for displaying image data representative of a structure. The imaging system comprises display rendering means for processing data representative of the configuration of the structure and rendering a display representative of the configuration of the structure. The display comprises image view panes displaying different image views. The rendering means are responsive to user interaction to display synchronously a predetermined sequence run of images at the view panes, in response to a user input stimulus. | 06-04-2009 |
20110010193 | ZOOM PANE FOR A CENTRAL MONITORING DEVICE - In a clinical environment, where multiple patients reside at any given time, central patient monitoring stations ( | 01-13-2011 |
20120151093 | SYSTEM AND METHOD TO SYNCHRONIZE A PATIENT MONITORING DEVICE WITH A CENTRAL SERVER - A patient monitoring device ( | 06-14-2012 |
Patent application number | Description | Published |
20100112546 | NANOSCALE SENSORS - Various aspects of the present invention generally relate to nanoscale wire devices and methods for use in determining analytes suspected to be present in a sample, and systems and methods of immobilizing entities such as reaction entities relative to nanoscale wires. In one aspect, a nucleic acid, such as DNA, may be immobilized relative to a nanoscale wire, and in some cases, grown from the nanoscale wire. In certain embodiments, the nucleic acid may interact with entities such as other nucleic acids, proteins, etc., and in some cases, such interactions may be reversible. As an example, an enzyme such as telomerase may be allowed to bind to DNA immobilized relative to a nanoscale wire. The telomerase may extend the length of the DNA, for instance, by reaction with free deoxynucleotide triphosphates in solution; additionally, various properties of the nucleic acid may be determined, for example, using electric field interactions between the nucleic acid and the nanoscale wire. In another aspect, the invention provides systems and methods for attaching entities such as nucleic acids, receptors such as gangliosides, or surfactants to a nanoscale wire, for example, using aldehyde-producing reactions or hydrophobic interactions. In some aspects, certain systems and methods of the present invention may be used to determine an analyte suspected to be present in a sample, for example, a toxin, a virus, or a small molecule. Systems and methods of using such nanoscale wires are disclosed in other aspects of the invention, for example, within a microarray. Still other aspects of the invention include assays, sensors, kits, and/or other devices that include such nanoscale wires, methods of making and/or using functionalized nanoscale wires (for example, in drug screening or high-throughput screening), and the like. | 05-06-2010 |
20100152057 | HIGH-SENSITIVITY NANOSCALE WIRE SENSORS - The present invention generally relates to nanoscale wire devices and methods for use in determining analytes suspected to be present in a sample. The invention provides a nanoscale wire that has improved sensitivity, as the carrier concentration in the wire is controlled by an external gate voltage, such that the nanoscale wire has a Debye screening length that is greater than the average cross-sectional dimension of the nanoscale wire when the nanoscale wire is exposed to a solution suspected of containing an analyte. This Debye screening length (lambda) associated with the carrier concentration (p) inside nanoscale wire is adjusted by adjusting the gate voltage applied to an FET structure, such that the carriers in the nanoscale wire are depleted. | 06-17-2010 |
20100227382 | Nanoscale sensors - Various aspects of the present invention generally relate to nanoscale wire devices and methods for use in determining analytes suspected to be present in a sample, and systems and methods of immobilizing entities such as reaction entities relative to nanoscale wires. In one aspect, a nucleic acid, such as DNA, may be immobilized relative to a nanoscale wire, and in some cases, grown from the nanoscale wire. In certain embodiments, the nucleic acid may interact with entities such as other nucleic acids, proteins, etc., and in some cases, such interactions may be reversible. As an example, an enzyme such as telomerase may be allowed to bind to DNA immobilized relative to a nanoscale wire. The telomerase may extend the length of the DNA, for instance, by reaction with free deoxynucleotide triphosphates in solution; additionally, various properties of the nucleic acid may be determined, for example, using electric field interactions between the nucleic acid and the nanoscale wire. In another aspect, the invention provides systems and methods for attaching entities such as nucleic acids, receptors such as gangliosides, or surfactants to a nanoscale wire, for example, using aldehyde-producing reactions or hydrophobic interactions. In some aspects, certain systems and methods of the present invention may be used to determine an analyte suspected to be present in a sample, for example, a toxin, a virus, or a small molecule. Systems and methods of using such nanoscale wires are disclosed in other aspects of the invention, for example, within a microarray. Still other aspects of the invention include assays, sensors, kits, and/or other devices that include such nanoscale wires, methods of making and/or using functionalized nanoscale wires (for example, in drug screening or high-throughput screening), and the like. | 09-09-2010 |
20140080139 | HIGH-SENSITIVITY NANOSCALE WIRE SENSORS - One aspect of the invention provides a nanoscale wire that has improved sensitivity, for example, as the carrier concentration in the wire is controlled by an external gate voltage. In one set of embodiments, the nanoscale wire has a Debye screening length that is greater than the average cross-sectional dimension of the nanoscale wire when the nanoscale wire is exposed to a solution suspected of containing an analyte. In certain instances, the Debye screening length associated with the carriers inside nanoscale wire may be adjusted by adjusting the voltage, for example, a gate voltage applied to an FET structure. In some cases, the nanoscale wire can be operated under conditions where the carriers in the nanoscale wire are depleted and the nanoscale wire has a conductance that is not linearly proportional to the voltage applied to the nanoscale wire sensor device, for example, via a gate electrode. | 03-20-2014 |
Patent application number | Description | Published |
20090326222 | BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES - Compounds of formula (I) | 12-31-2009 |
20100160258 | Bicyclic aryl sphingosine 1-phosphate analogs - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 06-24-2010 |
20100160357 | Heterobicyclic sphingosine 1-phosphate analogs - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 06-24-2010 |
20120190649 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 07-26-2012 |
20130059821 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the SIP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SIP receptors. | 03-07-2013 |
20140100195 | Heterobicyclic sphingosine 1-phosphate analogs - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 04-10-2014 |
20140275010 | QUATERNARY SALTS - The present invention provides quaternary salts, such as those of Formula I: | 09-18-2014 |
20140309190 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S | 10-16-2014 |
20140371209 | S1P Modulating Agents - Compounds of formula (I) or (II) can modulate the activity of SIP receptors. | 12-18-2014 |
20150232492 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 08-20-2015 |
20150329528 | Pladienolide Pyridine Compounds and Methods of Use - The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. | 11-19-2015 |
Patent application number | Description | Published |
20090003420 | SYSTEMS AND METHODS FOR EMBEDDING A FIRST SIGNAL IN THE CODING OF A SECOND SIGNAL - A method for embedding a first signal in the coding of a second signal is described. A value of the first signal is determined. A codebook based on the value of the first signal is generated. A second signal is encoded using a codeword from the generated codebook. The encoded second signal is modulated into a plurality of symbols, wherein the symbols are distributed according to the value of the first signal. The modulated symbols are inserted into one or more time slots of a sequence. | 01-01-2009 |
20090268843 | SYSTEMS AND METHODS FOR PROVIDING UNEQUAL MESSAGE PROTECTION - Input data may be coded in accordance with a coding method that allows for either coded data or messages to be transmitted with pre-determined, but unequal reliability over a communication channel. The coding method may allow the messages to be transmitted with higher reliability than the coded data. Messages may be transmitted when they are available. Otherwise, the coded data may be transmitted. | 10-29-2009 |
20100066573 | SYSTEMS AND METHODS FOR PROVIDING UNEQUAL ERROR PROTECTION USING EMBEDDED CODING - A method for embedded encoding of at least two types of information is described. A first message and a second message are received. The types of a first encoder and a second encoder are determined. The rates of the first encoder and the second encoder are determined. A first codeword and a second codeword are generated. A mapping rule for the second codeword and a coding rule for the first codeword are determined. The second codeword is mapped into a plurality of symbols using the mapping rule. A third codeword is determined using the first codeword, the plurality of symbols, and the coding rule. The third codeword is then transmitted. The third codeword includes at least two types of information. | 03-18-2010 |
20100235709 | SYSTEMS AND METHODS FOR PROVIDING UNEQUAL ERROR PROTECTION CODE DESIGN FROM PROBABILISTICALLY FIXED COMPOSITION CODES - A method of encoding that uses standard codecs such as linear encoders and decoders for encoding and decoding data with different levels of robustness to errors is described. In one configuration, multiple encoders may be utilized, and one of the encoders may use a standard encoder such as a turbo code followed by a nonlinearity that creates an unequal distribution of ones and zeros in a binary representation of the code. In another configuration, a coder may be utilized that represents message outputs as “channels” that create state transitions (or symbol errors) in a data forward error correction coder. | 09-16-2010 |
20110080880 | TRANSMISSION DIVERSITY SCHEME ON PHYSICAL UPLINK CONTROL CHANNEL (PUCCH) WITH ACK/NACK DIFFERENTIATION - A method for transmitting uplink control information (UCI) using a physical uplink control channel (PUCCH) transmit diversity scheme is described. A UCI is coded with a Forward Error Correction code to obtain a coded UCI. The coded UCI is mapped to quadrature phase shift keying (QPSK) symbols to obtain a mapped coded UCI. A phase shift pattern is selected. A phase shift from the phase shift pattern is applied to the mapped coded UCI based on an acknowledge/negative-acknowledge (ACK/NACK) to obtain a phase shifted mapped coded UCI. The mapped coded UCI is sent using a PUCCH resource on a first antenna. The phase shifted mapped coded UCI is sent using a PUCCH resource on a second antenna. | 04-07-2011 |
20110080903 | CODING A CONTROL MESSAGE WITH DETERMINED DATA CODE BLOCK REPETITION - A method for coding control data with user data repetition is disclosed. Bits in user data may be removed. Bits in control data may be repeated to increase a number of bits in the control data. A number of bits in the user data that is the same as the number of bits in the control data may be copied. The copied user data bits may be added to the control data. The user data and the control data may be multiplexed. | 04-07-2011 |
20120250788 | SPATIAL SPREADING IN A MULTI-ANTENNA COMMUNICATION SYSTEM - Spatial spreading is performed in a multi-antenna system to randomize an “effective” channel observed by a receiving entity for each transmitted data symbol block. For a MIMO system, at a transmitting entity, data is processed (e.g., encoded, interleaved, and modulated) to obtain N | 10-04-2012 |
Patent application number | Description | Published |
20090124993 | TREATING NEUROLOGICAL DISORDERS - Methods of treating neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders, with TWEAK or TWEAK-R blocking agents are presented. | 05-14-2009 |
20090311313 | METHODS FOR TREATING TWEAK-RELATED CONDITIONS - The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists. | 12-17-2009 |
20090317388 | Tl1a in treatment of disease - Methods of modulating TL1A for the treatment of disease are disclosed. | 12-24-2009 |
20110002924 | TWEAK RECEPTOR AGONISTS AS ANTI-ANGIOGENIC AGENTS - The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed. | 01-06-2011 |
20120014953 | TREATING AND EVALUATING INFLAMMATORY DISORDERS - Methods of treating inflammatory disorders, such as rheumatoid arthritis, by modulating TWEAK and TNF-α are disclosed, as are other methods. | 01-19-2012 |
20120015024 | METHODS FOR TREATING TWEAK-RELATED CONDITIONS - The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists. | 01-19-2012 |
20120183542 | TREATING NEUROLOGICAL DISORDERS - Methods of treating neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders, with TWEAK or a TWEAK receptor blocking agents are presented. | 07-19-2012 |
20130095175 | TREATING NEUROLOGICAL DISORDERS - Methods of treating neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders, with TWEAK or a TWEAK receptor blocking agents are presented. | 04-18-2013 |
20130216496 | METHODS FOR TREATING TWEAK-RELATED CONDITIONS - The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists. | 08-22-2013 |
20150291688 | Methods For Treating Tweak-Related Conditions - The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists. | 10-15-2015 |
Patent application number | Description | Published |
20100093732 | Acid Addition Salts, Hydrates and Polymorphs of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-is- oxazole-3-carboxylic Acid Ethylamide and Formulations Comprising These Forms - The present invention relates to new salt forms of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, in particular the mesylate, hydrochloride, tartrate, phosphate and hemi fumarate salt thereof; to crystalline forms of such salts; to polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations. | 04-15-2010 |
20120172592 | ACID ADDITION SALTS, HYDRATES AND POLYMORPHS OF 5-(2,4-DIHYDROXY-5-ISO-PROPYL-PHENYL)-4-(4-MORPHOLIN-4-YLMETHYL-PHENYL)-I- SOXAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE AND FORMULATIONS COMPROSING THESE FORMS - The present invention relates to new salt forms of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, in particular the mesylate, hydrochloride, tartrate, phosphate and hemi fumarate salt thereof; to crystalline forms of such salts; to polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations. | 07-05-2012 |
20130296556 | Acid Addition Salts, Hydrates and Polymorphs of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-is- oxazole-3-carboxylic Acid Ethylamide and Formulations Comprising These Forms - The present invention relates to new salt forms of | 11-07-2013 |
Patent application number | Description | Published |
20110251190 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE - The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula I | 10-13-2011 |
20130131035 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS - The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. | 05-23-2013 |
20140213581 | FUSED MULTI-CYCLIC SULFONE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF - The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: | 07-31-2014 |
20140296226 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use - The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A | 10-02-2014 |
20150259308 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE - The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A | 09-17-2015 |
20150266824 | Pyrazole Amide Derivative - The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases. | 09-24-2015 |
20150307521 | AMINO-OXAZINE AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE - The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A | 10-29-2015 |
Patent application number | Description | Published |
20130273034 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT - The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: | 10-17-2013 |
20130295051 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT - The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below. | 11-07-2013 |
20140248240 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) - The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: Formula (I) | 09-04-2014 |
20140275057 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT - The present invention relates to compounds and composition for inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below. | 09-18-2014 |
20140294805 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT - The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: | 10-02-2014 |
20150104384 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES - The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds. | 04-16-2015 |
20150175621 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES - Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds. | 06-25-2015 |
20160002266 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES - Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds. | 01-07-2016 |
Patent application number | Description | Published |
20130183688 | TIM-3 LIGANDS AND METHODS THEREOF - The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses. | 07-18-2013 |
20140348842 | TIM-3 LIGANDS AND METHODS THEREOF - The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses. | 11-27-2014 |
Patent application number | Description | Published |
20080240733 | DISPERSION COMPENSATOR FOR FREQUENCY RESHAPED OPTICAL SIGNALS - An optical transmitter is disclosed including an optical signal source generating a frequency modulated signal encoding data. An optical spectrum reshaper is positioned to receive the frequency modulated signal and converts the frequency modulated signal into a reshaped signal having increased amplitude modulation relative to the frequency modulated signal. A third-order dispersive element is positioned to receive the reshaped signal and is adapted to impose third-order dispersion on the reshaped signal to generate a compensated signal having third-order dispersion effective to compensate for second-order dispersion caused by an optical fiber positioned between the optical transmitter and a receiver. | 10-02-2008 |
20080247763 | CHIRPED LASER WITH PASSIVE FILTER ELEMENT FOR DIFFERENTIAL PHASE SHIFT KEYING GENERATION - A method for generating D-N-PSK optical signals is disclosed wherein a laser is modulated to generate optical signal pairs including phase modulated and fixed phase portions, the phase modulated portions having a frequency encoding one or more data symbols and the fixed phase portion having a carrier frequency and a phase corresponding to the immediately preceding phase modulated portion. The output of the laser is passed through an optical spectrum reshaper having a transmission function chosen to attenuate a plurality of the phase modulated portions relative to the fixed phase portions. The phase modulated portions may have N frequency levels located on either side of the carrier frequency. One of the N frequency levels may be equal to the carrier frequency. | 10-09-2008 |
20090060526 | OPTICAL FM SOURCE BASED ON INTRA-CAVITY PHASE AND AMPLITUDE MODULATION IN LASERS - An optical transmitter is discloses having a gain section and a phase section. The phase section is modulated to generate a frequency modulated signal encoding data. The frequency modulated signal is transmitted through an optical spectrum reshaper operable to convert it into a frequency and amplitude modulated signal. In some embodiments, a driving circuit is coupled to the phase and gain sections is configured to simultaneously modulate both the phase and gain sections such that the first signal is both frequency and amplitude modulated. | 03-05-2009 |
20100098436 | METHOD AND APPARATUS FOR GENERATING SIGNALS WITH INCREASED DISPERSION TOLERANCE USING A DIRECTLY MODULATED LASER TRANSMITTER - An optical transmitter is disclosed wherein a signal processor receives a data stream and outputs a drive signal for a laser, where the drive signal encodes each bit of the data stream according to the values of adjacent bits effective to compensate for spreading of bits within the fiber. The output of the laser is input to an optical spectrum reshaper that outputs a signal having an enhanced extinction ratio. | 04-22-2010 |
20100329666 | THERMAL CHIRP COMPENSATION IN A CHIRP MANAGED LASER - Thermal chirp compensation in a chirp managed laser. In one example embodiment, a method for thermal chirp compensation in a chirp managed laser (CML) includes several acts. First, a first bias condition and temperature is selected. Next, a first thermal chirp compensation signal is generated. Then, the laser is driven by biasing a first input drive signal with the first thermal chirp compensation signal. Next, a second bias condition and temperature is selected. Then, a second thermal chirp compensation signal is generated. Finally, the laser is driven by biasing a second input drive signal with the second thermal chirp compensation signal. | 12-30-2010 |
20110170171 | OPTICAL DIFFERENTIAL PHASE-SHIFT KEYED SIGNAL DEMODULATOR - A phase-shift keyed signal demodulator is disclosed including a filter positioned to receive an input beam, a first photodiode positioned to receive light reflected from the filter, and a second photodiode positioned to receive light transmitted through the filter. A difference between outputs of the first and second photodiodes is interpreted to determine a data value encoded in the input beam. In another embodiment N filters receive inputs from a splitter and include transmission functions offset from one another. N pairs of photo diodes receive the transmitted and reflected beams from each filter and a decoder converts the outputs of the pairs of photodiodes to one or more data symbols. | 07-14-2011 |
20120251130 | THERMAL CHIRP COMPENSATION IN A CHIRP MANAGED LASER - Thermal chirp compensation in a chirp managed laser. In one example embodiment, a laser package including a laser and an optical spectrum reshaper configured to convert frequency modulated optical signals from the laser into an amplitude modulated optical signals is provided. A thermal chirp compensation device is in communication with the laser package and a laser driver. The thermal chirp compensation device includes means for generating bias condition and temperature specific thermal chirp compensation signals that each corresponds to a predetermined level of thermal chirp that is induced in the laser by operating the laser at a particular bias condition and temperature. | 10-04-2012 |
20120269523 | OPTICAL DIFFERENTIAL PHASE-SHIFT KEYED SIGNAL DEMODULATOR - A phase-shift keyed signal demodulator and method for demodulating is disclosed. An example demodulator includes N filters that receive inputs from a splitter and include transmission functions offset from one another. N pairs of photodiodes receive the transmitted and reflected beams from each filter and a decoder converts the outputs of the pairs of photodiodes to one or more data symbols. | 10-25-2012 |
20130094797 | Optical Transmitter With Tunable Chirp - An optical transmitter with chirp control includes an input polarizer having an input that receives an optical signal. The input polarizer polarizes the optical signal along an input polarization axis. A Mach-Zehnder modulator includes an optical input that is coupled to an output of the input polarizer and an electrical input that receives a modulation signal. The Mach-Zehnder modulator modulates the optical signal with the modulation signal. The input polarization axis of the input polarizer is chosen to achieve a desired chirp of the modulated optical signal. An output polarizer is coupled to the output of the Mach-Zehnder modulator. The output polarizer polarizes the modulated optical signal along a desired output polarization axis that combines TE and TM mode polarizations. | 04-18-2013 |
20140185139 | Birefringent Crystal Polarization Beam Splitter Assembly - An optical apparatus, comprising a polarization beam splitter (PBS) comprising a birefringent crystal having a front-end and a back-end, and an optical rotator positioned on the back-end of the birefringent crystal. Included is an optical apparatus comprising a PBS comprising a birefringent crystal and an optical rotator, wherein the PBS is configured to receive a multiplexed optical signal comprising a first polarized optical signal and a second polarized optical signal, wherein the second polarized optical signal is orthogonal to the first polarized optical signal, separate the first polarized optical signal from the second polarized optical signal using the birefringent crystal, and rotate the second polarized optical signal using the optical rotator such that the rotated second polarized optical signal is parallel to the first polarized optical signal. The PBS may further comprise only one lens, wherein the lens is positioned on the front-end of the birefringent crystal. | 07-03-2014 |
20140185253 | Miniature High Density Opto-Electronic Package - A method comprising coupling a circuit to an opto-electronic package via an anisotropic conductive film (ACF), wherein the opto-electronic package is configured to communicate electrical signals via the coupling at a maximum frequency of about 10 gigahertz (GHz) to about 40 GHz. An apparatus comprising, an opto-electronic package comprising a plurality of first electrodes, and a circuit comprising a plurality of second electrodes, wherein at least one of the first electrodes is coupled to at least one of the second electrodes via an ACF, and wherein the opto-electronic package is configured to communicate electrical signals via the coupling at a maximum frequency of about 10 GHz to about 40 GHz. | 07-03-2014 |
20150132007 | Digital Optical Modulator for Programmable n-Quadrature Amplitude Modulation Generation - An optical transceiver comprising an optical signal input, a first modulation section coupled to the optical signal input, a second modulation segment coupled to the optical signal input and positioned in serial with the first modulation section, wherein the first modulation section comprises a first digital electrical signal input, a first digital driver coupled to the first digital electrical signal input, and a first modulator coupled to the first digital driver, and wherein the second modulation section comprises a second digital electrical signal input, a second digital driver coupled to the second digital electrical signal input, and a second modulator coupled to the second digital driver, and an optical signal output coupled to the first modulation section and the second modulation section. | 05-14-2015 |
20150285997 | Edge Coupling Using Adiabatically Tapered Waveguides - An apparatus comprising a thick waveguide comprising a first adiabatic tapering from a first location to a second location, wherein the first adiabatic tapering is wider at the first location than at the second location, and a thin slab waveguide comprising a second adiabatic tapering from the first location to the second location, wherein the second adiabatic tapering is wider at the second location than at the first location, and a third adiabatic tapering from the second location to a third location, wherein the third adiabatic tapering is wider at the second location than at the third location, wherein at least a portion of the first adiabatic tapering is adjacent to the second adiabatic tapering, and wherein the first adiabatic tapering and the second adiabatic tapering are separated from each other by a constant gap. | 10-08-2015 |
Patent application number | Description | Published |
20080272001 | PRODUCTION LINE TREATMENT FOR ORGANIC PRODUCT - A fluid from a fermentation process or the like is passed or circulated through chambers of a bipolar membrane electrodialysis unit to separate an ionizable organic acid stream and at least one co-ion or residual stream. The organic acid stream is preferably concentrated (e.g., by recirculation, dewatering or both), and a product is recovered from the concentrated stream, for example by crystallization, and other outputs from the electrodialysis unit may be integrated with overall treatment and applied elsewhere in the treatment system. Depleted feed may be returned upstream to enhance yield, condition the medium or form a by-product. Treatment systems of the invention may replace a cation exchange bed and/or various filter arrangements, and recirculation of the feed and product flows through the unit enhance recovery, separation and quality of the target species. An ED chamber may include a filling of ion exchange beads to maintain a desired operating efficiency as the feed is depleted, and the straight-through operation effectively operates as pre-filtration stage to provide downstream product-bearing flows with processing characteristics for enhanced treatment, recovery and product quality. When operated to treat a downstream waste, systems allow additional recovery of value in the form of product, unexpended nutrients, co-factors and/or other components present in the waste. | 11-06-2008 |
20120165419 | ACID BLOCK ANION MEMBRANE - Acid block anionic selective polymeric membranes are provided of the type having a woven or non-woven cloth reinforcing structure. The polymer of the membrane is prepared by the process comprising copolymerizing components I, II, and III wherein I is an ethylenically unsaturated aliphatic or aromatic tertiary or quaternary amine monomer. II is a cross-linking monomer, and III is vinylbenzyl chloride. The reaction is conducted in the presence of a free radical polymerization initiator. Additionally, anionic exchange membranes of the type used in electrodialysis apparatus are disclosed and comprise a woven or nonwoven cloth that is impregnated with a copolymer comprising the reaction products of components I, II, and III. | 06-28-2012 |
Patent application number | Description | Published |
20120243751 | BASELINE FACE ANALYSIS - Facial information is collected on a person and used to analyze affect. Facial information can be used to determine a baseline face which characterizes the default expression that a person has on their face. Deviations from this baseline face can be used to evaluate affect and further be used to infer mental states. Facial images can be automatically scored for various expressions including smiles, frowns, and squints. Image descriptors and image classifiers can be used during this baseline face analysis. | 09-27-2012 |
20130102854 | MENTAL STATE EVALUATION LEARNING FOR ADVERTISING - Analysis of mental states is performed as people view advertisements. Advertisement effectiveness is evaluated based on the analyzed mental states. Learning is then performed to determine the most effective ways to evaluate mental states based on the evaluation methods' ability to project advertisement effectiveness. Effectiveness descriptors are evaluated and statistics are assembled for the advertisements. One or more effectiveness classifiers are determined. Based on the effectiveness descriptors and classifiers, advertisement effectiveness is projected. | 04-25-2013 |
20130151333 | AFFECT BASED EVALUATION OF ADVERTISEMENT EFFECTIVENESS - Analysis of mental states is provided in order to enable data analysis pertaining to affect-based evaluation of advertisement effectiveness. Advertisements can have various objectives, including entertainment, education, awareness, persuasion, startling, or a drive to action. Data, including facial information, is captured for an individual viewer or group of viewers. Physiological information may also be gathered for the viewer or group of viewers. In some embodiments, demographics information is collected and used as a criterion for rendering the mental states of the viewers in a graphical format. In some embodiments data captured from an individual viewer or group of viewers is used to optimize an advertisement. | 06-13-2013 |